Cargando…

Feasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases

BACKGROUND: In stereotactic radiotherapy, dose is prescribed to an isodose surrounding the planning target volume (PTV). However, the desired dose inhomogeneity inside the PTV leaves the specific dose distribution to the gross tumor volume (GTV) unspecified. A simultaneously integrated boost (SIB) t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kornhuber, Christine, Ensminger, Stephan, Hübsch, Patrick, Janich, Martin, Leucht, Chris Andre, Vordermark, Dirk, Dietzel, Christian T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204235/
https://www.ncbi.nlm.nih.gov/pubmed/37217934
http://dx.doi.org/10.1186/s13014-023-02266-9
_version_ 1785045791695437824
author Kornhuber, Christine
Ensminger, Stephan
Hübsch, Patrick
Janich, Martin
Leucht, Chris Andre
Vordermark, Dirk
Dietzel, Christian T.
author_facet Kornhuber, Christine
Ensminger, Stephan
Hübsch, Patrick
Janich, Martin
Leucht, Chris Andre
Vordermark, Dirk
Dietzel, Christian T.
author_sort Kornhuber, Christine
collection PubMed
description BACKGROUND: In stereotactic radiotherapy, dose is prescribed to an isodose surrounding the planning target volume (PTV). However, the desired dose inhomogeneity inside the PTV leaves the specific dose distribution to the gross tumor volume (GTV) unspecified. A simultaneously integrated boost (SIB) to the GTV could solve this shortcoming. In a retrospective planning study with 20 unresected brain metastases, a SIB approach was tested against the classical prescription. METHODS: For all metastases, the GTV was isotropically enlarged by 3 mm to a PTV. Two plans were generated, one according to the classical 80% concept with 5 times 7 Gy prescribed (on D(2%)) to the 80% PTV surrounding isodose (with D(98%)(PTV) ≥ 35 Gy), and the other one following a SIB concept with 5 times 8.5 Gy average GTV dose and with D(98%)(PTV) ≥ 35 Gy as additional requirement. Plan pairs were compared in terms of homogeneity inside GTV, high dose in PTV rim around GTV, and dose conformity and gradients around PTV using Wilcoxon matched pairs signed rank test. RESULTS: The SIB concept was superior to the classical 80% concept concerning dose homogeneity inside GTV: Heterogeneity index of GTV was in the SIB concept (median 0.0513, range 0.0397–0.0757) significantly (p = 0.001) lower than in the 80% concept (median 0.0894, range 0.0447–0.1872). Dose gradients around PTV were not inferior. The other examined measures were comparable. CONCLUSION: Our stereotactic SIB concept better defines the dose distribution inside PTV and can be considered for clinical use.
format Online
Article
Text
id pubmed-10204235
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102042352023-05-24 Feasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases Kornhuber, Christine Ensminger, Stephan Hübsch, Patrick Janich, Martin Leucht, Chris Andre Vordermark, Dirk Dietzel, Christian T. Radiat Oncol Research BACKGROUND: In stereotactic radiotherapy, dose is prescribed to an isodose surrounding the planning target volume (PTV). However, the desired dose inhomogeneity inside the PTV leaves the specific dose distribution to the gross tumor volume (GTV) unspecified. A simultaneously integrated boost (SIB) to the GTV could solve this shortcoming. In a retrospective planning study with 20 unresected brain metastases, a SIB approach was tested against the classical prescription. METHODS: For all metastases, the GTV was isotropically enlarged by 3 mm to a PTV. Two plans were generated, one according to the classical 80% concept with 5 times 7 Gy prescribed (on D(2%)) to the 80% PTV surrounding isodose (with D(98%)(PTV) ≥ 35 Gy), and the other one following a SIB concept with 5 times 8.5 Gy average GTV dose and with D(98%)(PTV) ≥ 35 Gy as additional requirement. Plan pairs were compared in terms of homogeneity inside GTV, high dose in PTV rim around GTV, and dose conformity and gradients around PTV using Wilcoxon matched pairs signed rank test. RESULTS: The SIB concept was superior to the classical 80% concept concerning dose homogeneity inside GTV: Heterogeneity index of GTV was in the SIB concept (median 0.0513, range 0.0397–0.0757) significantly (p = 0.001) lower than in the 80% concept (median 0.0894, range 0.0447–0.1872). Dose gradients around PTV were not inferior. The other examined measures were comparable. CONCLUSION: Our stereotactic SIB concept better defines the dose distribution inside PTV and can be considered for clinical use. BioMed Central 2023-05-22 /pmc/articles/PMC10204235/ /pubmed/37217934 http://dx.doi.org/10.1186/s13014-023-02266-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Kornhuber, Christine
Ensminger, Stephan
Hübsch, Patrick
Janich, Martin
Leucht, Chris Andre
Vordermark, Dirk
Dietzel, Christian T.
Feasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases
title Feasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases
title_full Feasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases
title_fullStr Feasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases
title_full_unstemmed Feasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases
title_short Feasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases
title_sort feasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204235/
https://www.ncbi.nlm.nih.gov/pubmed/37217934
http://dx.doi.org/10.1186/s13014-023-02266-9
work_keys_str_mv AT kornhuberchristine feasibilityofasimultaneouslyintegratedboostconceptforhypofractionatedstereotacticradiotherapyofunresectedbrainmetastases
AT ensmingerstephan feasibilityofasimultaneouslyintegratedboostconceptforhypofractionatedstereotacticradiotherapyofunresectedbrainmetastases
AT hubschpatrick feasibilityofasimultaneouslyintegratedboostconceptforhypofractionatedstereotacticradiotherapyofunresectedbrainmetastases
AT janichmartin feasibilityofasimultaneouslyintegratedboostconceptforhypofractionatedstereotacticradiotherapyofunresectedbrainmetastases
AT leuchtchrisandre feasibilityofasimultaneouslyintegratedboostconceptforhypofractionatedstereotacticradiotherapyofunresectedbrainmetastases
AT vordermarkdirk feasibilityofasimultaneouslyintegratedboostconceptforhypofractionatedstereotacticradiotherapyofunresectedbrainmetastases
AT dietzelchristiant feasibilityofasimultaneouslyintegratedboostconceptforhypofractionatedstereotacticradiotherapyofunresectedbrainmetastases